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Hypoxia describes limited oxygen availability at the cellular level. Myeloid cells are exposed to
hypoxia at various bodily sites and even contribute to hypoxia by consuming large amounts of
oxygen during respiratory burst. Hypoxia-inducible factors (HIFs) are ubiquitously expressed het-
erodimeric transcription factors, composed of an oxygen-dependent 𝛼 and a constitutive 𝛽 sub-
unit. The stability ofHIF-1𝛼 andHIF-2𝛼 is regulatedbyoxygen-sensing prolyl-hydroxylases (PHD).
HIF-1𝛼 andHIF-2𝛼modify the innate immune response and are context dependent.We provide a
historic perspective of HIF discovery, discuss the molecular components of the HIF pathway, and
howHIF-dependent mechanisms modify myeloid cell functions. HIFs enable myeloid-cell adapta-
tion to hypoxia by up-regulating anaerobic glycolysis. In addition to effects on metabolism, HIFs
control chemotaxis, phagocytosis, degranulation, oxidative burst, and apoptosis. HIF-1𝛼 enables
efficient infection defense bymyeloid cells. HIF-2𝛼 delays inflammation resolution and decreases
antitumor effects by promoting tumor-associated myeloid-cell hibernation. PHDs not only con-
trol HIF degradation, but also regulate the crosstalk between innate and adaptive immune cells
thereby suppressing autoimmunity. HIF-modifying pharmacologic compounds are entering clini-
cal practice. Current indications include renal anemia and certain cancers. Beneficial and adverse
effects on myeloid cells should be considered and could possibly lead to drug repurposing for
inflammatory disorders.
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1 INTRODUCTION
Myeloid cells consist of granulocytes, mostly neutrophils, and mono-
cytes. Once released from the bone marrow, these cells circulate in
the blood and are recruited to inflammatory sites where they execute
functions that protect the host from infectious and noninfectious chal-
lenges.Myeloid cells perform efficiently even under hostile conditions,
such as extreme temperatures, mechanical and osmotic stress, and
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low oxygen concentration. Hypoxia describes low oxygen availability
at the tissue level that is further categorized into hypoxemic, anemic,
circulatory, and histotoxic hypoxia.1 During their life span, myeloid
cells encounter awide range of oxygen partial pressures. Bonemarrow
is a rather hypoxic niche with 13 mm Hg mean oxygen tension.2
Measurements in healthy humans indicate a large variation in partial
oxygen pressures with 100 mm Hg in arterial blood and 8 mm Hg in
the epidermis (reviewed in Ortiz-Prado et al.3). Kidneys exhibit a large
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gradient with>70mmHg in the cortex and 10mmHg in the medulla.4
Importantly, hypoxia is also characteristic of inflamed tissues,5,6 where
activatedmyeloid cells migrate against a low oxygen supply.7
With reduced oxygen supply, mitochondrial oxidative phosphoryla-
tion is strongly decreased, andmost ATP is provided by the conversion
of pyruvate into lactate.7 Hypoxia-inducible factors (HIFs) are ubiqui-
tous transcriptional regulators of gene expression in response to low
oxygen availability. HIFs help myeloid cells to cope with low oxygen
conditions by modifying several metabolic and inflammatory aspects.
Currently, drugs that either activate or inhibit HIF-mediated effects
are being explored in clinical studies. We discuss the HIF system with
its implications for myeloid cell functions together with the potential
effects of HIF-directed treatments.
2 HISTORIC PERSPECTIVE OF HIF
DISCOVERY
The scientific interest in hypoxia dates back to Paul Bert, who identi-
fied hypoxemic hypoxia as the cause of altitude sickness in the second
half of the 19th century.8,9 Over decades, hypoxia-mediated effects
on erythropoiesis became a main research focus that more recently
extended to inflammation. However, it took more than a century
until molecular hypoxia mechanisms were characterized, the termHIF
was introduced10 and pharmacologic HIF modulators were developed
along a timeline outlined in Fig. 1.
In 1906, Carnot reported a serum factor extracted from anemic
rabbits that stimulated erythropoiesis in recipient animal bone mar-
row and termed this putative factor “hémopoïétine.”11,12 Yet, the
nature of this factor remained elusive for several decades. In the
1950s, Jacobson suggested that erythropoietin (EPO) was secreted
by the kidneys.13 The investigators observed that bilateral nephrec-
tomy abrogated the erythropoietic effect of CoCl2 in rats and
rabbits.14 Later, the liver was identified as an additional extrarenal
EPOsource.15–22 Most clinical observations supported the importance
of the kidneys for erythropoiesis with complete erythroblastopenia
in anuric renal failure patients23 and after nephrectomy,24 and poly-
cythemia in patients with renal pathologies, such as renal cysts, hyper-
nephroma, or hydronephrosis.25–33 In the 1970s, EPO was isolated
from the urine of anemic patients34–36 followed by cloning and recom-
binant expression a decade later.37–42 Allan Erslev and his research led
to the discovery of EPO.43 The hormone causes the body tomakemore
red blood cells and is now the pivotal drug to treat anemia caused by
cancer therapy, dialysis, and kidney disease. Erslev made rabbits ane-
mic.Whenhe injected their anemic plasma intonormal rabbits, the rab-
bits increased production of red blood cells and as the number of red
blood cells increased so hematocrit increased. In contrast, injection of
normal plasma into normal rabbits did not lead to an increase in red
blood cells. Erslev concluded that a hormone (EPO) was responsible
for the increase in red blood cells. Yet, the molecular mechanisms of
hypoxia-regulated EPO transcription and, as it later turned out, many
additional genes were still unknown.
In the late 1980s, Goldberg et al. suggested a ferroprotein as
the oxygen sensor.44 The investigators used metals (i.e., manganese,
nickel,45–48 and cobalt as CoCl2) that interact with protoporphyrin
structures and compete with iron in heme prosthetic groups to induce
EPO.44,49 Locking heme-bearing proteins in a deoxy conformation
with these metals induced EPO mRNA and protein. Hypoxia was not
synergistic with this deoxy state, whereas carbon monoxide, which
created an oxy state of hemoglobin, reduced the EPO-enhancing effect
of hypoxia. Together, these experiments led to the reasonable assump-
tion that the cellular oxygen sensor is a heme protein. However, as it
turned out later, the free iron was bound to a nonheme protein that
was yet to be discovered.
In the 1990s, reporter assays unmasked cis-acting elements
responsive to hypoxia.50,51 Transgenic mice carrying the human EPO
gene produced nuclear factors selectively binding to 3′ flanking
sequences of the human EPO transgene.10 Consecutive mutational
analysis of a 50 nt 3′ flanking sequence of the human EPO gene
revealed a proteinaceous DNA binding that the authors termed
HIF-1.10 HIF-1 was characterized as a protein complex generated
in hypoxic cells that binds to a DNA sequence crucial for hypoxic
activation of EPO transcription.52,53 More than 10 yr passed until
prolyl-hydroxylase domain containing enzymes (PHD) were finally
identified as the long-assumed sensor of cellular oxygen tension that
regulate HIF abundance. Although the earlier suggested iron-binding
domain was confirmed, the implied heme-involving mechanism was
not.54–57 In 2019,WilliamG. Kaelin Jr., Sir Peter J. Ratcliffe, and Gregg
L. Semenza received the Nobel Prize for explaining how cells sense
and adapt to different oxygen concentrations.
3 MOLECULAR HIF PATHWAY
COMPONENTS
3.1 HIF𝜶 subunit isoforms and dimerization
with aryl hydrocarbon receptor nuclear
translocator (ARNT)
HIFs are transcription factors with an N-terminal basic helix-loop-
helix (bHLH) followed by a Per-ARNT-Sim (PAS) domain58 and
C-terminal transcription activation domains. HIFs function mostly as
heterodimers consisting of HIF𝛽 , formerly named ARNT58,59 and one
of three HIF𝛼 subunits.53,60,61 Similar to other members of bHLH-
PAS transactivators,62 the basic domain is indispensable for DNA
binding63,64 by recognizing the consensus core sequence of hypoxia-
response elements (HRE): 5′-TACGTG-3,65,66 whereas the HLH and
PAS domains promote 𝛼 and 𝛽 heterodimerization.58,64 However, the
PAS-A domain also enhances DNA binding of the HIF heterodimer
illustrating the synergistic interplay of elements from the entire bHLH-
PAS region.64 Studying fusionandchimeric proteinsofHIF𝛼monomers
revealed additional domains, namely two oxygen-dependent degrada-
tiondomains (ODD)67–69 aswell as two transactivationdomains,N ter-
minal transactivation domain (N-TAD) and C terminal transactivation
domain (C-TAD).64,70–72 HIF structure details are illustrated in Fig. 2.
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F IGURE 1 Timeline andmilestones of hypoxia-inducible factors (HIFs) discovery
3.2 Oxygen-dependent HIF regulation by
proteasomal degradation
The HIF𝛼 isoforms and HIF-1𝛽 are all constitutively transcribed and
translated. The cellular abundance of the former, but not the latter, is
controlled by oxygen concentration. Under normoxic conditions, the
HIF𝛼 proteins reside in the cytoplasm where they interact with heat
shock protein (Hsp)90 through the bHLH-PAS domain.73–75 However,
under normoxia, HIF𝛼 proteins are continuously degraded in the
proteasome mediated by the von-Hippel-Lindau (pVHL) protein.76
pVHL serves as a substrate-recognizing subunit of an E3 ubiquitin
ligase complex54,77,78 and forms a ternary complex with elongins
B and C79 thereby recruiting Cul-2 and Rbx-1.80–82 The resulting
multimeric complex acquires E3 ligase activity and, in concert with
the E1 ligase Uba and the E2 ligases Ubc5a, Ubc5b, and Ubc5c,83
leads to oxygen- and iron-dependent ubiquitination and subse-
quent proteasomal degradation of the HIF𝛼 subunits.57,84,85 Mass
spectrometry established that hydroxylation of proline residues
within the HIF ODD was indispensable for pVHL recognition of
degradation-designated HIF𝛼 subunits under normoxic conditions.
Subsequently, new dioxygenase isoforms were identified that
were responsible for posttranslational oxygen-dependent HIF𝛼
hydroxylation.55 Thus, the cellular oxygen sensor was finally charac-
terized as PHD. C. elegans expresses a HIF system that is homologous
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F IGURE 2 Schematic of hypoxia-inducible factor (HIF)-1𝜶 and HIF-2𝜶 protein structure and hydroxylation sites at proline and asparagine
residues. The basic submotif and the helix-loop-helix domain (bHLH) are located close to the N terminus, followed by the Per-ARNT-Sim (PAS)
domain. The PAS domain comprises repetitive amino acid sequences PAS-A and -B. The oxygen-dependent degradation domain (ODD) overlaps
with theN terminal transactivation domain (N-TAD), followed by the C terminal transactivation domain (C-TAD). Hydroxylation of proline residues
within theODDandof asparagine residueswithin theC-TADofHIF-1𝛼 andHIF-2𝛼 are highlighted. Thenonequilibriumhydroxylationby theprolyl-
hydroxylases (PHD) and the asparagine hydroxylase factor inhibiting HIF-1 (FIH-1) including substrates and products is depicted exemplarily for
two of the three hydroxylation sites of HIF-1𝛼









































F IGURE 3 Hypoxia-inducible factor (HIF) pathway components and regulating mechanisms in myeloid cells. HIF𝛼 and HIF𝛽 subunits are
constitutively transcribed and translated. The HIF-1𝛼 antisense strand transcript ahif decreases HIF𝛼 protein expression. In hypoxia, nonhydrox-
ylated HIF𝛼 dimerizes with HIF𝛽 and binds to hypoxia-response elements (HRE) enhancing target gene transcription upon recruitment of co-
transactivators, including CREB-binding protein (CBP) and p300. Under normoxia, prolyl-hydroxylase domain-containing enzymes (PHD) hydrox-
ylate HIF𝛼 subunits, thus enabling von-Hippel-Lindau gene product (pVHL) binding to HIF𝛼 subunits and subsequent proteasomal degradation.
Factor inhibiting HIF-1 (FIH-1)-mediated HIF𝛼 hydroxylation under normoxia prevents HIF𝛼 association with indispensable co-transactivators
for target gene transcriptional enhancement. Phosphorylated receptor of activated protein kinase C (RACK1) induces HIF𝛼 proteasomal degra-
dation, which is inhibited by endothelin-receptor-dependent calcineurin activation. NO inhibits PHD activity. Hypoxia, infectious (gram-positive
bacteria as blue circles, gram-negative bacteria in red) and noninfectious (endothelin in violet and ET receptor) stimuli activate the HIF pathway in
myeloid cells
to humans and was instrumental in PHD characterization. The egl-9
gene, so named because of a presumed egg-laying defect of the gene-
deficient worm, encodes an oxygen-dependent prolyl-hydroxylase
and egl-9-deficient mutants up-regulated the human HIF homolog
constitutively.56 Subsequently, three human PHD isoforms were iden-
tified, encoded by the genes EGLN1 (egg-laying defective nine homolog
1), EGLN2, and EGLN3, respectively.86 A conserved 2-histidine-1-
carboxylate motif serves as iron-binding structure.56 The catalyzed
proline-4-hydroxylation requires dioxygen, divalent iron (Fe2+), and
the co-substrates 2-oxoglutarate and ascorbate.55,87 PHDs catalyze
HIF-1𝛼 hydroxylation at Pro40267 and Pro564,57 whereas HIF-2𝛼 is
hydroxylated at Pro405 and Pro531.67 Site-specific proline hydroxyla-
tion by PHDs is controlled by both an LXXLAP amino acid motif of the
target protein and cellular oxygen availability.56,67 PHD activities are
inhibited by co-substrate competitors such as dimethyloxalylglycine57
and roxadustat88,89 as well as products of the nonequilibrium reaction
such as succinate.87,90 PHD inhibition is of particular interest in
inflammation as reactive oxygen species (ROS) that are produced
in this process induced HIF stabilization irrespective of normoxia.91
ROS-dependent 2-oxoglutarate decarboxylation to succinate,91 pros-
thetic Fe2+ oxidation,92 and disulfide-bond PHD dimerization93 were
discussed as underlying PHD inhibitionmechanisms.
Despite cellular hypoxic adaptation by the HIF pathway, HIF
abundancy and target gene expression are also under the control of
oxygen-independent mechanisms. HSC70, LAMP2a, and Cezanne94
concertHIF-1𝛼 lysosomal degradationby cyclin-dependent kinase reg-
ulated chaperone-mediated autophagy.95,96 The HIF subunit specific
E3 ubiquitin ligases hypoxia-associated factor97 and mammary tumor
integration site 6 (Int6)98 initiate HIF-1𝛼, and HIF-2𝛼 proteasomal
degradation irrespective of oxygen tension and pVHL, respectively.
3.3 Oxygen-dependent HIF regulation by
transcriptional inhibition
In addition to directing HIF degradation, oxygen controls the trans-
activation efficacy of HIF heterodimers by factor inhibiting HIF-1
(FIH-1).99 FIH-1 is an asparaginyl-hydroxylase belonging to the same
oxygen- and 2-oxoglutarate-dependent dioxygenase superfamily as
the PHDs.100 However, FIH-1 activity persists even under hypoxic
conditions of 1% oxygen when PHD2 activity is abolished.101 Under
normoxic oxygen tensions, FIH-1 hydroxylates Asn803 of HIF-1𝛼,
and Asn851 of HIF-2𝛼, respectively.102 These hydroxylation sites are
located within the C-TAD. Their hydroxylation prevents indispensable
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co-transactivator recruitment that initiate target gene transcription.
Fig. 3 depicts important components of the HIF pathway.
3.4 HIF-regulated target genes and signaling
pathways
CREB-binding protein (CBP) and p300 bind to HIF𝛼/𝛽 heterodimers
with nonhydroxylated asparagine residues in the C-TAD.101,103,104
All HIF𝛼 isoforms recognize the same HRE 5′-TACGTG-3′ motif, but
result in unique differential target gene expression105 with the N-TAD
determining target gene selectivity.106,107 Nonetheless, comparison of
cell-specific target gene regulation highlighted the importance of the
cell type for the HIF-controlled transcriptome.106,107
HIF-1𝛼 primarily controlsmetabolic pathways, including adaptation
to anaerobic energy supply by up-regulating glycolysis and the hexose
monophosphate pathway.108–110 These effects facilitate cell survival
in low-oxygen conditions. In addition, HIF-1𝛼 regulates apoptosis-
related genes, for example, members of the B-cell lymphoma 2 (BCL-2)
family,111 and proinflammatory genes including IL-1𝛽 ,112 IL-6,113 and
IL-8.114 HIF-1𝛼 also prevents excessive cellular reactions to hypoxia
by up-regulating PHD transcription.115,116
In contrast, HIF-2𝛼 fine-tunes embryonic development and cellular
differentiation.105 Despite the initial discovery of HIF-1 in the context
of EPO expression, we and others have shown predominant EPO tran-
scriptional control by HIF-2.117,118
4 HIF-CONTROLLED MYELOID CELL
FUNCTIONS IN HUMANS
Human neutrophils express all PHD isoforms119 and do not express
HIF-1𝛼 protein under normoxia.120 However, neutrophil HIF-1𝛼
protein is induced at low oxygen tensions.120 Some,120 but not all
studies121 described HIF-2𝛼 expression in human granulocytes under
normoxia with preserved response to hypoxia. Possibly, differences
are explained by the use of different culture media as for example the
presence of the NO donor GEA3162120 inhibits PHD activity.122,123 In
human monocytes, hypoxic induction of the HIF-1𝛼 natural antisense
transcript ahif contributes to a negative feedback mechanism on
HIF-1𝛼 activity.124
Evolutionary adaptation of high-altitude populations, as well as
monogenetic mutations affecting the HIF pathway, provide insight
in HIF-controlled mechanisms that help myeloid cells to cope with
low oxygen concentrations and to maintain their functions. Additional
information comes from human individuals or isolated myeloid cells
exposed to hypoxia.
4.1 Adaptive genetic variations in HIF pathway
components provide an opportunity to study
consequences formyeloid cell functions
Despite living above 4000 m, Tibetan communities, in contrast to
communities residing at similar altitudes in the Andes, have mostly
normal red-blood-cell and hemoglobin values. A missense mutation
in the EGLN1 gene results in a PHD2 variant with a lower Km and
higher Vmax value for oxygen.
125,126 Consequently, HIF hydroxylation
is facilitated even under hypoxia. Other studies in Tibetans correlated
SNPs in EPAS1 (HIF-2𝛼) with hemoglobin levels127–129 and SNPs in
the EGLN3 (PHD3) and PPP1R2P1 (protein phosphatase 1 regulatory
inhibitor subunit 2) genes with altitude polycythemia.130 However,
these Tibetan adaptations of the HIF pathway provide an interesting
opportunity to study myeloid cell functions, immunity, and inflamma-
tory disorders.
Chuvash polycythemia, named after the Chuvash republic in
Russia, is another endemic genetic variation of the HIF pathway
accompanied by elevated EPO and VEGF plasma levels.131 The C598T
base exchange in the third VHL exon causes a missense mutation
(R200W)132 that stabilizes predominantly HIF-2𝛼 over HIF-1𝛼.133
Th1 (IL-2, IL-12, IFN𝛾 , TNF𝛼, GM-CSF) and Th2 cytokine (IL-4, IL-5,
IL-10, IL-13) plasma levels in affected individuals were found to be
elevated together with decreased CD4+ T-cell frequency and reduced
CD4/CD8 ratio.132 Transcriptome analysis in PBMCs from Chuvash
polycythemia patients showed up-regulatedHIF target genes involved
in the inflammatory response (TNF𝛼, IL-1𝛽 , TLR4) as well as in myeloid
cell differentiation, phagocytosis, and bacterial defense (FCGR2A,
HCK, GAB2, ITGB).131 Pro-apoptotic genes (CASP8, CASP2) and TCR
elements were down-regulated.131 The reasons for the apparent
discrepancy between TCR down-regulation found in this131 and
increased Th1 and Th2 cytokines in the other study132 are not clear.
Myeloid cell functions in the Chuvash polycythemia cohort have not
been investigated.
4.2 Genetic diseases highlight the interplay of
metabolism andHIF pathway components
Patients with VHL syndrome harbor heterozygous germline VHL
mutations predisposing to hemangiomas, paragangliomas, and renal
carcinomas. Neutrophils from these patients showed decreased
spontaneous apoptosis as well as increased phagocytic activity against
bacteria.134X Hypoxia further enhanced these functions in both VHL
neutrophils and cells from healthy controls.134 Thus, VHL neutrophils
showed a partial hypoxic phenotype under normoxic conditions
indicating that HIF indeed regulates neutrophil functions. However,
whether or not enhanced neutrophil function contributes to the
clinical phenotype of patientswith theVHL syndrome remains unclear.
Glycogen storage disease Ib (GSD1b) is characterized by a nonfunc-
tional glucose-6-phosphate transporter, neutropenia, and recurrent
infections. Myeloid cells135 fromGSD1b patients comprise a defective
energy metabolism leading to endoplasmic reticulum stress with Hsp
induction and elevated ROS.136 In some of the GSD1b patients, con-
stitutive neutrophil HIF-1𝛼 stabilization, attributed to the Hsp90 and
ROS increase, was observed.137 Nevertheless, the metabolic impair-
ment in GSD1b neutrophils led to accelerated constitutive apoptosis,
reduced respiratory burst, phagocytosis, and chemotaxis despite
stabilized HIF-1𝛼.135,136 As expected, HIF stabilization improves
cellular energy supply that is indispensable for neutrophil survival and
66 KLING ET AL.
functioning. In fact, HIF-1𝛼 target genes, including peroxisome
proliferator-activated receptor 𝛾 (PPAR𝛾), were up-regulated in
GSD1b neutrophils. PPAR𝛾 up-regulation contributed to neutrophil
dysfunction because PPAR𝛾 inhibition improved chemotaxis and
the respiratory burst.137 Accordingly, neutrophils isolated from
healthy controls mimicked GSD1b-associated neutrophil dysfunc-
tion upon pharmacologic HIF stabilization and PPAR𝛾 activation by
rosiglitazone.137 These data suggest that HIFs control myeloid cell
functions not only by providing cellular energy supply but also through
PPAR𝛾 activation.
Succinate is a powerful PHD inhibitor inasmuch as it is an end
product of the hydroxylation reactions mediated by PHDs.90 Patients
with heterozygous germline mutations of succinate dehydrogenase B
(SDHB) had elevated succinate levels in neutrophils and their effects
on the HIF pathway were analyzed.138 Neutrophil glycolytic activ-
ity and HIF-1𝛼 protein expression did not differ from healthy con-
trols under normoxic culture conditions but were increased with
hypoxia. However, neutrophils from patients with SDHB deficiency
demonstrated a reduced apoptotic rate and a lower intracellular ROS
stress under both normoxia and hypoxia that could be mimicked in
control neutrophils by selective inhibition of SDHB.138 These obser-
vations suggest that the neutrophil phenotype was caused by the
metabolic consequences of the SDHB mutation and not by HIF path-
way activation. Theobservations obtained in neutrophils frompatients
with these Mendelian diseases underscore the importance of HIF-
dependent effects on neutrophil survival and functions. However,
these studies reveal additional HIF-independent metabolic pathways
that modify HIF-dependent actions.
4.3 Exposure of human individuals to hypoxia
enhancesmyeloid cell performance
Several studies investigated myeloid cells isolated from healthy vol-
unteers who were exposed to hypoxic conditions before blood
donation. Following hypoxic donor exposure neutrophil phagocytosis
increased139–142 and decreased with normoxia.143–147 More mech-
anistically, low oxygen tension increased cytokine-induced expres-
sion of phagocytosis receptors on the neutrophil surface, including Fc
receptors CD32w, CD16, CD64, and complement receptor CD35.146
Other phagocytic receptors (C5aR, CD16b) and adhesion molecules
(LFA-1, L-selectin) were also up-regulated.139,140,142
Blood donor hypoxia increased stimulated respiratory
burst,140,148,149 chemotactic motility,139 and degranulation in isolated
neutrophils.149 However, plasma neutrophil elastase (NE), IL-1, IL-6,
and IL-8,149 and ROS concentration in resting blood neutrophils150
were not increased.
Together, these experiments indicate that hypoxia exposure of
humans, which leads to HIF stabilization, enhances inflammatory
myeloid cell functions. However, these observations cannot estab-
lish that HIFs play a causal role in this process. Another caveat
is that although the blood donors were exposed to hypoxia, iso-
lated myeloid cells were studied under normoxia. Conceivably,
normoxia led to rapid HIF degradation of in vivo stabilized HIFs,
whereas HIF-induced effects on transcription and metabolism may
have persisted.
4.4 Myeloid-cell exposure to hypoxia in vitro
prolongs survival and increases activation responses
Several studies analyzed neutrophils thatwere isolated fromnormoxic
donors and exposed to hypoxia in vitro. McGovern and coworkers
found that hypoxic culture of human neutrophils did not affect the
secretion of IL-6, IL-8, TNF𝛼, or IL-10,151 whereas ROS-dependent
bactericidal activity was reduced. Limited molecular oxygen lead-
ing to reduced NADPH oxidase-dependent respiratory burst was the
possible explanation for the latter observation. In contrast, ROS-
independent killing by hypoxic neutrophils was increased.151
Hypoxia augmented the release of granule proteins from activated
neutrophils as shown for NE,151 myeloperoxidase, lactoferrin, and
matrix metalloproteinase-9 (MMP-9).152 Consequently, supernatants
from activated hypoxic neutrophils caused more epithelial cell dam-
age compared to normoxic neutrophils.152 The hypoxic degranulation
increasewas reduced by a selective PI3K𝛾 inhibitor that abrogated the
hypoxic degranulation augmentation.152 The fact that pharmacologic
HIF stabilization by PHD inhibitors did notmimic augmented degranu-
lationand increasedepithelial cell injury seenwithhypoxic neutrophils,
questions a causal role for HIF but does not exclude involvement of
components upstream fromHIFmediated by PHDs or FIH-1.
Hypoxic inhibition of constitutive neutrophil apoptosis in vitro was
reported by several investigators121,134,151,153,154 possibly via HIF-
1𝛼 mediated NF𝜅B activation.121 By contrast, other groups reported
HIF-1𝛼 stabilization to be downstream of NF𝜅B155 or mammalian
target of rapamycin activation.156–158 Anoxia also attenuated TNF𝛼-
accelerated neutrophil apoptosis in vitro. Moreover, hypoxic culture
conditions abrogated the pro-apoptotic effect of synovial fluid from
rheumatoid arthritis patients on healthy control neutrophils.159
Hypoxia also has effects on monocytes and macrophages that, sim-
ilar to neutrophils, express HIFs.124,160–162 Hypoxia up-regulated the
LPS163- and phytohemagglutinin-induced164 secretion of proinflam-
matory cytokines IL-8,163 IL-2, IL-4, IL-6, and IFN𝛾 , whereas anti-
inflammatory IL-10 was repressed.164 HIF-1𝛼-mediated 𝛽2-integrin
up-regulation enhanced monocyte adhesion to endothelial cells under
hypoxia.165
Hypoxia increasedefferocytosis, thephagocytosis of apoptotic neu-
trophils bymonocytes ormacrophages. This effect was, at least in part,
mediated by HIF-1𝛼-dependent induction of the class B scavenger
receptor CD36 and its ligand thrombospondin-1 conveying apoptotic
material.166 HIF-mediated CD36 induction is supported by the obser-
vation that CD36 and HIF-1𝛼 expressing macrophages correlated in
biopsies from patients with inflammatory bowel disease.166
Altogether, these studies support the notion that hypoxia exposure
in vitro prolongs myeloid cell survival and promotes proinflammatory
responses that are important for host defense. The exact role of HIFs
in these adaptiveprocesses remains unclear andneeds tobeaddressed
in animal studies that allowHIFmanipulations.
KLING ET AL. 67
5 HIF-CONTROLLED MYELOID CELL
FUNCTIONS—LESSONS FROM ANIMAL
EXPERIMENTS
5.1 Hypoxicmodulation ofmyeloid cells controls
inflammation in animals
Various animal models were employed to study oxygen-dependent
modifications ofmyeloid cell-driven inflammation. In rats, hypoxic pre-
conditioning protected the animals from gastrointestinal ischemia-
reperfusion injury, including bacterial translocation.167 Neutropenic
rats lacked the protective effect suggesting a neutrophil-dependent
mechanism.167 In agreement with this suggestion, neutrophils con-
sumed oxygen during respiratory burst thereby creating a hypoxic
environment for epithelial cells that promoted HIF stabilization and
induction of HIF target genes. As a result, the epithelial barrier
was increased.168 Neutrophils from NADPH oxidase gene-deficient
chronic granulomatous disease (CGD) mice are unable to produce
superoxide anions and therefore did not create a hypoxic environ-
ment. Consequently, CGD neutrophils did not increase the epithelial
barrier and CGD mice displayed a more severe phenotype of chemi-
cal colitis.168 Further evidence supportingHIF driven epithelial barrier
stabilization is provided by murine colitis models showing beneficial
effects of PHD inhibitors.168–172
5.2 Inflammatory andmechanical challenges
imitate oxygen-dependent HIF stabilization
Myeloid cell studies in animals elucidated HIF stabilizing mechanisms
above and beyond hypoxia. Bacterial antigens from gram-negative and
gram-positive species173,174 as well as TLR4 stimulation by LPS158
stabilized HIFs inmyeloid cells. Mechanistically, combined PHDdown-
regulation and up-regulation of HIF transcription were suggested to
increase HIF proteins.162,173,174 More recently, HIF induction by phys-
ical forces was reported in murine bone marrow-derived monocytes.
Cyclical hydrostatic pressure, for example, due to in- and expiration,
activated the monocytic ion channel PIEZO1 leading to paracrine
endothelin-1 secretion. Subsequently, endothelin receptor stimulation
activated calcineurin that dephosphorylated receptor of activated
protein kinase C (RACK1).175 Phosphorylated RACK1 competes with
cytoplasmic Hsp90 for binding HIF𝛼 subunits and promotes their
proteasomal degradation.176,177 Finally, mechanotransduced RACK1
dephosphorylation contributed to HIF-1𝛼 protein accumulation.175
5.3 HIF-1𝜶 improvesmyeloid cell functions in
infectious and noninfectious inflammationmodels
Myeloid-specific HIF-1𝛼 gene deletion severely reduced intracellular
ATP concentrations in murine macrophages and neutrophils leading
to reduced intracellular bactericidal activity,173 adhesion, and motility
of monocytes.7 HIF-1𝛼 gene-deficient murine neutrophils displayed
decreased NE and cathepsin G activities that were restored by VHL
deletion, hence, by constitutive HIF-1𝛼 stabilization.173 Likewise,
pharmacologic HIF stabilization by PHD inhibition enhanced mono-
cyte bactericidal properties in murine skin abscesses by inducing
monocytic cathelicidin and IL-8 production.178 HIF-1𝛼 gene-deleted
myeloid cells demonstrated decreased killing of Helicobacter pylori
resulting in aggravated murine H. pylori gastritis.113 Biopsies from
patients with H. pylori gastritis showing local macrophage HIF-1𝛼
stabilization strengthened the clinical significance of myeloid HIF-1𝛼
for providing antibacterial defense.113
We demonstrated HIF-1𝛼 and HIF-2𝛼 up-regulation in human
psoriatic skin lesions.179 Compared to control mice, myeloid-specific
HIF-1𝛼 gene deficiency caused ameliorated leukocyte skin infiltra-
tion in bacterial173 and chemical7 skin inflammation, alleviated acute
pathologyof chemical colitiswith reducedmacrophage infiltration, and
reduced colonic TNF𝛼, IFN𝛾 , and IL-17 expression.180,181 Conflicting
results were reported in ARNTflox/flox: LysM-Cremice. Thesemice that
were not able to form HIF heterodimers showed prolonged myeloid
cell infiltration in a colitis model despite expected acceleratedmyeloid
cell apoptosis.182 Pronounced numbers of infiltrating cells were possi-
bly explained by colonic up-regulation of antiapoptotic factors serum
amyloid A3 and leukotriene B4 in the inflamed colon sections.182
LPS-induced HIF-1𝛼 up-regulated proinflammatory cytokines IL-1,
IL-4, IL-6, IL-12, and TNF𝛼 in macrophages resulting in increased
mortality in murine sepsis.174 Acute hypoxic HIF stabilization at
inflammation induction increased mortality in murine skin infection
and pneumonia models.183 Complementarily, myeloid-specific HIF-
1𝛼 gene-deletion reduced shock and hypothermia in murine sepsis
and decreased mortality,174,183 whereas hypoxia prior to infection
improved infection control.183 Hypoxic preconditioning for 1 wk
induced a myeloid cell memory effect as bone marrow from these
hypoxic mice reduced sepsis morbidity in normoxic recipients.183
Together, these results imply a temporal component of HIF activation
that determines the outcome of infection and systemic inflammation.
Hypoxic preconditioning prior to the infection reduced inflamma-
tion, whereas HIF activation at the onset of inflammation induced
collateral damage.
In addition to infection, reparative healing processes after physical
trauma also depend on the HIF pathway in myeloid cells. Myeloid
HIF-1𝛼 gene deletion delayed macrophage-driven resorption of mus-
cle necrosis leading to reduced revascularization of the regenerated
muscle tissue.184 In contrast, myeloid-specific HIF𝛼 subunit stabi-
lization in VHLflox/flox: LysM-Cre mice preserved myocardial muscle
integrity in fullyMHC-mismatchedmurine cardiac allotransplantation,
at least in part, by myeloid HIF𝛼 stabilization-dependent production
of anti-inflammatory IL-10. In addition, myeloid-derived suppressor
cells reduced T-cell proliferation. Ultimately, HIF signaling reduced
acute rejection and ischemia-reperfusion injury leading to prolonged
allograft survival.185
Synovial tissue from rheumatoid arthritis patients161,186 and exper-
imental arthritis mice5 both up-regulated HIFs and myeloid-specific
HIF-1𝛼 andHIF-2𝛼 genedeficiency alleviated inflammation in amurine
rheumatoid arthritismodel.7,186 Neutrophils isolated fromrheumatoid
arthritis patients showed enhanced PHD2 and PHD3 mRNA expres-
sion in line with induction of proinflammatory HIF target genes.119
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However, myeloid HIF pathway activation as well as myeloid HIF defi-
ciency did not affect the rheumatoid arthritis-associated uveitis phe-
notype in an intravitreal LPS-induced mouse model.187 Conceivably,
this discrepancy is due to the divergent inflammatory stimuli under-
scoring the importance of the inflammatory context.
5.4 HIF-2𝜶mitigatesmyeloid cell destructive
capacity, but prolongs inflammation
In contrast toHIF-1𝛼 deletion,myeloid-specificHIF-2𝛼 genedeficiency
in mice did not affect ATP generation in macrophages.188 However,
macrophage motility and tissue infiltration were significantly dimin-
ished accompanied by down-regulation of chemokine receptor CXCR4
and fibronectin-1.188 Secretion of proinflammatory cytokines IL-1𝛽 ,
IL-6, IL-12, TNF𝛼, and CXCL2 following stimulation with IFN𝛾 or LPS
was significantly decreased, whereas these mice up-regulated anti-
inflammatory IL-10 upon LPS injection.188
Studies in a murine LPS-induced acute lung injury model revealed
differential effects of the HIF𝛼 subunits during neutrophil-mediated
inflammation. A HIF-2𝛼 gain-of-function mutation did not affect
neutrophil effector functions such as oxidative burst and phago-
cytosis but decreased constitutive apoptosis similar to what was
aforementioned for HIF-1𝛼.120 Acute pulmonary inflammation pre-
dominantly induced neutrophil HIF-1𝛼 at an early stage, whereas
HIF-2𝛼 induction was prominent during the resolution phase. Myeloid
HIF-2𝛼 gene deficiency shortened and alleviated pulmonary inflam-
mation, particularly in later stages of acute lung injury, presumably by
increased neutrophil apoptosis.120 Inflammation models in zebrafish
with HIF-2𝛼 gain-of-function mutation and myeloid-specific HIF-2𝛼
gene-deficientmice further underscored the fact thatHIF-2𝛼 prolongs
inflammation.120,182,188
We previously demonstrated that HIF-2𝛼 controls EPO
transcription.117 In addition to its role in erythropoiesis, EPO
was proposed to have anti-inflammatory effects. In a murine peri-
tonitis model, hypoxia induced EPO as well as EPO receptors (EPOR)
on infiltrating macrophages.189 Macrophage EPOR signaling led to
PPAR𝛾 activation thereby inducing anti-inflammatory cytokines,
down-regulating proinflammatory cytokines, enhancing macrophage
efferocytosis and phagocytosis. CGD mice that were unable to mount
a respiratory burst and therefore did not consume oxygen failed to
develop peritoneal hypoxia. Consequently, endogenous EPO was not
induced.189 Exogenous EPO therapy restricted peritoneal inflamma-
tion. The authors discuss this observation as a consequence of HIF-1𝛼,
despite the fact that EPO is rather a HIF-2𝛼 target gene.
Tumor-associated macrophages and neutrophils (TAM and TAN)
contribute to the progression of solid tumors. We showed previ-
ously that these cells also promoted chronic lymphatic leukemia in a
murine disease model and that selective depletion of myeloid subpop-
ulations retarded leukemia progression.190 TAM express HIF-2𝛼160
and several observations suggest that HIF-2𝛼 restrains their anti-
cancer effects. Thus, HIF-2𝛼flox/flox: LysM-Cre mice developed fewer
chemically induced colon carcinomas.188 In contrast, the number
and size of chemically induced hepatocellular carcinomas were not
reduced in HIF-2𝛼-deficient mice, but both tumor entities demon-
strated lower grading, delayed tumor progression, and decreased
mitotic indices compared to wild-type (WT) mice.188 Moreover,
tumor histology showed a significant reduction of TAM numbers in
HIF-2𝛼-deficient mice, in line with HIF-2𝛼-dependent macrophage
invasiveness mentioned earlier.188 Conceivably, HIF-2𝛼-dependent
macrophage cytokine secretion possibly accounts for the observed
tumor cell proliferation reduction and lower grading in HIF-2𝛼-
deficient mice. More recently, a murine endometrial cancer model
established the importance of the hypoxic tumor microenvironment
for controlling TAN tumoricidal properties. Tumor hypoxia prevented
neutrophil NADPH-oxidase-dependent ROS production and MMP-9
secretion, which both promoted tumor cell sloughing by detachment
from the basement membrane.191 Hyperoxia reduced HIF in tumors
and increased neutrophil antitumor actions. Mechanistically, ROS and
MMP-9 were increased, whereas NE secretion was reduced result-
ing in diminished tumor cell proliferation.191 Thus, hyperoxia reversed
neutrophil hibernation in hypoxic tumors enhancing myeloid cell anti-
tumor effects independent of adaptive immune cells.191
5.5 Genetic PHD deletion controls myeloid cell
metabolism survival, andmyeloid cell-mediated
inflammation
Myeloid-specific gene-deletion of PHD enzymes facilitated the inves-
tigation of the HIF pathway in innate immunity in vivo. PHD2 is the
most critical regulator of HIFs.192 Deciphering PHD2 involvement in
myeloid cell-mediated inflammation and immunity in vivo is compli-
cated by the fact that homozygous PHD2 gene-deletion (PHD2−/−)
is embryonically lethal.193 Myeloid-specific PHD2 deletion using
PHD2flox/flox: LysM-Cre mice highlighted that PHD2 controls both
neutrophil metabolism and inflammatory neutrophil responses.194
PHD2 gene-deleted neutrophils up-regulated HIF-1𝛼 protein, but not
HIF-2𝛼, delayed constitutive apoptosis, and increased chemotactic
motility while phagocytic activity was unaltered. Absence of PHD2
enhanced typical HIF-1𝛼 target genes that increase glucose uptake,
glycogen storage, and glycolytic flux, culminating in an augmented
extracellular acidification rate by lactate generation and increased
intracellular ATP levels. Pharmacologic glycolysis inhibition reduced
neutrophil chemotaxis and survival, suggesting a mechanistic link
between these metabolic changes and the neutrophil effector
functions.194 Myeloid-specific PHD2 gene deficiency resulted in ear-
lier and faster pulmonary neutrophil recruitment in acute lung injury
models compared to WT controls. In addition, pulmonary inflamma-
tion persisted longer because of delayed neutrophil apoptosis rather
than reduced efferocytosis.194 Prolonged neutrophil persistence due
to HIF stabilization was also demonstrated in chemical colitis induced
in heterozygous PHD2+/− mice.194 It was suggested that the delayed
apoptosis in PHD2 gene-deficient neutrophils is mediated by IL-4
and the neutrophil IL-4 receptor. In WT mice, but presumably not
in PHD2 gene-deficient mice, IL-4 treatment reverses hypoxia- and
HIF-1𝛼-mediated neutrophil apoptosis delay by PPAR𝛾-dependent
PHD2 up-regulation. Thus, IL-4-dependent PHD2 expression limited
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inflammation and promoted its resolution.195 In another study,
inducible PHD2 knock-down in mice, stabilizing both HIF-1𝛼 and
HIF-2𝛼, resulted in a lupus-like phenotypewith antinuclear antibodies,
leukocytosis, spontaneous weight loss, dermal lymphohistiocytic
infiltration, splenomegaly, and lymphadenopathy. The phenotype
depended largely on intact HIF-2𝛼 as combined PHD2 and HIF-2𝛼
shRNA-induced knockdown completely prevented the pathology.
Hematopoietic cells were the main contributors to the phenotype
as shown by bone marrow chimeric mice. Mechanistically, defective
suppressive functionality of regulatory T cells (Treg) explained the
autoimmune phenomena.196 By contrast, others reported that den-
dritic cell HIF-1𝛼 was indispensable for Treg induction and Treg tissue
recruitment by HIF-1𝛼-controlled homing receptor expression.197
These observations suggest that a postnatal inducible model, but
not constitutive myeloid-specific PHD2 gene-deletion resulted in a
spontaneous autoimmune phenotype that was linked to HIF-2𝛼 con-
trolling interactions of innate and adaptive immune cells. PHD1−/−
micewere also protected from chemical colitis.198 In human ulcerative
colitis tissue intestinal PHD1 expression correlated with the degree
of inflammation,198,199 which is also consistent with a protective role
of HIF.
However, several murine genetic PHD3 deletion models revealed
opposite effects with increased intestinal inflammation and decreased
mucosal integrity. PHD3 inhibits the E3 ubiquitin-ligase Itch that
orchestrates occludin-proteasomal degradation. Enterocyte-specific
PHD3 gene-deleted (PHD3IEC-KO) mice developed spontaneous
colitis without intestinal up-regulation of HIF𝛼 subunits, suggesting
compensation by PHD2 or PHD1.87,200 PHD3 contributes to the
mucosal barrier by securing epithelial occludin expression in the bowel
independent of HIF stabilization.200 PHD3-dependent intestinal
inflammation is further suggested by colonic biopsies from ulcerative
colitis patients showing inverse correlation of local inflammation with
PHD3 expression.199,200
Under normoxic conditions, neutrophil inflammation was unaf-
fected in PHD3−/− mice in LPS-induced acute lung injury or chemical
colitis.119,198 Hypoxic conditions significantly reduced neutrophil
lung and colon infiltration, possibly by hypoxia-induced PHD1 and 2
expression with subsequent HIF hydroxylation and degradation.119
PHD3−/− mice demonstrated normal white blood cell count and
granulocyte functioning, but neutrophil apoptosis was increased due
to up-regulated pro-apoptotic SIVA1 and suppressed antiapoptotic
BCL-XL, thereby contributing to decreased numbers of infiltrating
neutrophils.119 The role of HIFs was not explicitly established. In
contrast to neutrophils, PHD3 gene deficiency severely affected
murine monocyte functionality by enhancing migration and phagocy-
tosis in zymosan-induced peritonitis also under normoxia.201 PHD3
gene-deficient macrophages demonstrated pronounced HIF-1𝛼
and NF𝜅B activation polarizing macrophages toward a proinflam-
matory M1 phenotype. PHD3−/− mice as well as mice with PHD3
gene deficiency in hematopoietic cells only, were more susceptible
to sepsis by LPS injection or cecal ligation with higher mortal-
ity rate compared to WT, PHD1−/−, and PHD2+/− haplodeficient
mice. Moreover, monocytic tissue infiltration and peripheral blood
cytokines (TNF𝛼, IL-1𝛽) were increasedwhereas neutrophil infiltration
remained unaffected.201
Together, these studies indicate that PHD2 links innate and adap-
tive immunity. PHD2-dependent HIF-regulation is indispensable for
limiting inflammation and autoimmunity. PHD1 and PHD3 reduce
inflammation by preserving mucosal barriers with some of these
effects being possibly HIF independent. PHD3 keeps specifically
monocytes in check. Reasons for differential PHD effects remain ill-
defined but could be related to cell type, HIF𝛼 subunit, and HIF-
independent effects on additional pathways.
6 PHARMACOLOGIC HIF MODIFIERS
Strategies to either stabilize or reduce HIFs are of major clinical
interest and are currently explored in clinical studies. Given the
profound HIF effects on myeloid cells, it will be important to carefully
observe the effect of these pharmacologic substances on inflammation
and immunity.
6.1 HIF stabilization
HIF stabilization is a new strategy currently tested in renal anemia
patients. Various compoundsweredeveloped to inhibit PHD-mediated
HIF𝛼 hydroxylation and subsequent degradation. PHD inhibitors that
compete with the indispensable PHD co-substrates, including iron and
2-oxoglutarate are now available. These substances comprise roxadu-
stat (FG-4592),88,89 vadadustat (AKB-6548),202 molidustat (Bay85-
3934),203 daprodustat (GSK1278863),204 desidustat (ZYAN1),205
AKB-4924,171 and JNJ1935.206 Most of these compounds are cur-
rently investigated in phase 2 and phase 3 clinical trial programs for
renal anemia treatment. Of note, roxadustat treatment was associ-
ated with an increased rate of upper respiratory infections compared
to standard therapy with recombinant human EPO in phase 3 study in
dialysis-dependent patients with kidney disease (18.1% vs. 11.0%).89
Beyond the correction of renal anemia, preclinical evidence
suggests that PHD inhibition offers novel opportunities for organ
protection, an area of unmet clinical need. We showed potent
PHD inhibition by 2-(1-chloro-4-hydroxyisoquinoline-3-carbox-
amido)acetate (ICA) with beneficial effects in murinemodels of kidney
ischemia-reperfusion injury, allotransplantation, and chronic kidney
disease.207–210 Tissue and organ protective effects of PHD inhibition
have also been demonstrated in models of myocardial injury,211 brain
injury,212 lung injury,213 and—as mentioned earlier—inflammatory
bowel disease.169,172 AKB-4924 is evaluated for the treatment of
inflammatory bowel disease (NCT02914262).
6.2 HIF inhibition
Cancer research incentivized the development of HIF inhibitors.
Agents that inhibit HIF heterodimerization, DNA binding, or trans-
activation are classified as direct HIF inhibitors, whereas indirect
HIF inhibitors reduce HIF de novo synthesis or increase proteasomal
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degradation.214,215 Various compounds were reported in the litera-
ture (as reviewed in Bhattarai et al. and Ban et al.214,215), but only
a few substances are currently available for clinical applications. PT-
2385 is a direct HIF-2𝛼 inhibitor interfering with the HIF-2𝛼-ARNT
heterodimerization that is currently under investigation for treatment
of renal cell carcinoma (NCT02293980, NCT03108066) and glioblas-
toma (NCT03216499).216 Furthermore, in vitro testing of the HIF
inhibitor PX-478 in prostate carcinoma cells217 and a phase I clini-
cal trial enrolling lymphoma and solid cancer patients (NCT00522652)
were reported.
7 CONCLUDING REMARKS
Human and animal data implicate HIFs as important regulators of
myeloid cell metabolism, survival, and functioning. HIFs modify both
the magnitude and the duration of the inflammation response. PHDs
regulate HIF activity, preserve epithelial barrier function, and provide
a bridge between innate and adaptive immunity thereby controlling
autoimmunity. HIF pathway-modifying drugs are entering clinical
medicine. Given the emerging evidence for the role of theHIF pathway
in inflammation, patients should be monitored for inflammatory com-
plications. At the same time, the opportunity may arise to repurpose
HIF-modifying drugs for the treatment of inflammatory disorders.
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